Press Release: Organogenesis : Organogenesis Provides Update on Second Phase 3 ReNu Study
Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3...
Read full article »
President & CEO
Gary S. Gillheeney Sr.
Organogenesis is a Massachusetts-based regenerative medicine company that develops bioactive and acellular biomaterials products to treat orthopedics and spine diseases.
Read more